Login to Your Account

Astellas acquires R&D partner Mitobridge in $450M dea

By David Ho
Staff Writer

Wednesday, December 6, 2017

HONG KONG – Astellas Pharma Inc. is exercising its rights in a previous partnership agreement to acquire its R&D collaborator Mitobridge Inc. for $450 million.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription